Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥18.00 - ¥34.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥7.76B

Enterprise Value¥5.97B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding408,243,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Stronger EquityZero reported debt and a material increase in equity provide a durable capital cushion, reducing near-term solvency risk and giving management flexibility to prioritize R&D, pursue partnerships, or support clinical programs without immediate refinancing pressure. This structural balance sheet strength extends strategic optionality if cash burn moderates or funding needs arise.

Focused Oncology R&D ModelA specialized oncology research and drug-discovery focus aligns the company with a large, persistent unmet medical need and allows concentrated allocation of limited resources to high-value programs. This strategic focus supports durable competitive positioning among niche biotech peers and increases the potential upside from successful clinical or licensing milestones over the medium term.

Improved Gross Margin In 2026Movement to slightly positive gross margin signals operational progress such as better cost control, improved program economics, or favorable product mix. If sustained, this reduces the fixed-cost burden per revenue dollar, improves leverage from future sales or partnerships, and makes the path to operational breakeven more achievable as programs scale or commercial opportunities materialize.

Bears Say

Deep Negative Cash Flow / Cash BurnConsistently negative operating and free cash flow demonstrates losses are producing real cash outflows rather than non-cash accounting items, increasing reliance on external financing or equity raises. Structurally, this pressures runway, elevates dilution risk, and constrains the firm's ability to fund R&D or scale operations without securing new capital or strategic partnerships.

Revenue Volatility And Recent DeclineVolatile and declining revenue undermines predictability for funding development programs and impedes multiyear planning. Structural revenue instability increases execution risk for advancing clinical programs or securing licensing deals, complicates budgeting for commercial readiness, and can make it harder to demonstrate sustainable progress to partners or investors over the medium term.

Persistent Large Operating LossesOperating losses roughly equal to revenue indicate the current cost structure and business scale are insufficient to achieve positive operating leverage. Even with margin improvement, persistent negative net margins imply a prolonged path to self-sustaining profitability absent material clinical successes, commercialization, or substantial strategic partnerships that alter revenue or cost dynamics.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥18.00 and its highest was ¥34.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥7.76B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 181 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 408,243,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.